Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia.
Vincent Lévy, Tushar Srivastava, Raju Gautam, Shilpi Swami, Kaijun Wang, Keri Yang, Leyla Mohseninejad
Leuk Lymphoma 66(10) 1884-1892
摘要
摘要
Zanubrutinib demonstrated significantly longer progression-free survival versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in the ALPINE trial. This post-hoc analysis using ALPINE data aimed to understand the benefit-risk associated with zanubrutinib versus ibrutinib employing quality-adjusted time without symptoms/toxicity (Q-TWiST) methodology. Survival data were partitioned into 3 health-states: TOX (time with toxicity); TWiST (time without symptoms/toxicity); and REL (time after relapse). Q-TWiST was estimated as mean time in each health-state weighted by respective utility score. In the base case, comprising high-risk patients, mean durations (in months) for zanubrutinib versus ibrutinib were 11.54 versus 11.38 (TOX), 14.45 versus 11.09 (TWiST), and 1.70 versus 3.78 (REL). Mean duration of Q-TWiST was 21.07 (zanubrutinib) versus 18.67 months (ibrutinib; difference: 2.40 months; 95%CI: 1.9-2.9; p<.001). This analysis demonstrated a significant Q-TWiST gain for zanubrutinib versus ibrutinib in high-risk R/R CLL patients, providing valuable insights that may inform clinical decision-making.
KM 提取结果
0 个 Figure · 0 个 KM 面板